XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenues:    
Total revenue $ 164.9 $ 173.1
Costs and expenses:    
Research and development expense 21.2 23.1
Selling, general, and administrative expense 110.6 146.4
Goodwill and long-lived asset impairment charges 10.7 0.0
Total costs and expenses 190.5 219.8
Operating loss (25.6) (46.7)
Other income (expense):    
Interest income 0.1 0.2
Interest expense (0.9) (3.0)
Other 0.0 (0.1)
Total other income (expense), net (0.8) (2.9)
Loss before income tax (26.4) (49.6)
Income tax benefit (5.9) (10.1)
Net loss (20.5) (39.5)
Net loss attributable to non-controlling interest 0.0 0.0
Net loss attributable to Myriad Genetics, Inc. stockholders $ (20.5) $ (39.5)
Net loss per share:    
Basic (in dollars per share) $ (0.26) $ (0.52)
Diluted (in dollars per share) $ (0.26) $ (0.52)
Weighted average shares outstanding:    
Basic (shares) 80.1 76.0
Diluted (shares) 80.1 76.0
Molecular diagnostic testing    
Revenues:    
Total revenue $ 164.9 $ 159.6
Costs and expenses:    
Cost of revenue 48.0 44.1
Pharmaceutical and clinical services    
Revenues:    
Total revenue 0.0 13.5
Costs and expenses:    
Cost of revenue $ 0.0 $ 6.2